Track Myriad Genetics's current assets ($310M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), MYGN shows a current assets of $310M. That compares with $290M in the prior-year period — up 8.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MYGN's current assets is now $310M (was $290M) — a 8.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Myriad Genetics is outperforming or lagging.
Tracking MYGN's current assets over time shows whether Myriad Genetics is scaling, shrinking, or reshaping that part of the business. The current reading is $310M That compares with $290M in the prior-year period — up 8.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current assets page, Stockcircle has Myriad Genetics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $310M) with ownership activity and broader fundamentals.
Myriad Genetics's current assets is $310M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.